321 Arsenal Street
Suite 301 Building 312
Watertown, MA 02472
United States
339 217 0161
https://www.iteostherapeutics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 157
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Michel Detheux Ph.D. | President, CEO & Director | 1.04M | N/D | 1967 |
Mr. Matthew Gall | Chief Financial Officer | 648k | N/D | 1977 |
Mr. Matthew A. Call M.B.A. | Chief Operating Officer | 706.21k | N/D | 1973 |
Dr. Yvonne McGrath Ph.D. | Chief Scientific Officer | N/D | N/D | 1974 |
Ms. Adi Osovsky | Executive Vice President of Legal | N/D | N/D | N/D |
Mr. Philippe Brantegem | Executive Vice President of Human Resources | N/D | N/D | N/D |
Dr. Joyson Joseph Karakunnel FACP, M.D., M.Sc. | Interim Chief Medical Officer | N/D | N/D | 1971 |
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
La calificación ISS Governance QuickScore de iTeos Therapeutics, Inc. a partir del 1 de junio de 2024 es 8. Las puntuaciones principales son Auditoría: 7; Junta: 6; Derechos del accionista: 8; Compensación: 8.